Revenue segments as reported by the company.

Online Revenue

Wholesale Revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing

Operations and support

Technology and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Hims & Hers Health

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Hims & Hers Health achieves record revenue and profitability growth

Hims & Hers Health shows strong financial performance with revenue growth and profitability milestones.
The company's focus on customer-centric strategies, brand building, and innovation drives growth.
Challenges include competition in new categories and maintaining margins on personalized products.
Opportunities lie in expanding product offerings, improving customer experience, and leveraging efficiencies.

Hims & Hers Health excels in Q1 earnings, eyes strategic growth

Hims & Hers Health delivered robust financial performance in Q1 2023, driven by revenue growth, improved margins, and disciplined expense management.
The company's strengths lie in its focus on trusted brands, innovation in product offerings, and commitment to clinical excellence, fostering consumer trust and loyalty.
While challenges like insurance reimbursement and new category entries exist, they present opportunities for strategic growth and market differentiation in the healthcare sector.

Hims & Hers Health (HIMS) reports robust Q2 earnings, eyes personalized healthcare growth

Hims & Hers Health delivered strong financial performance in Q2, driven by revenue growth, expanded gross margins, and operational efficiency. While facing short-term challenges from pricing investments, the company remains focused on long-term growth through personalized treatments and new category launches. Opportunities lie in leveraging consumer trends towards personalized healthcare and expanding product offerings.

Hims & Hers Health reports robust Q3 performance and growth opportunities

Hims & Hers Health (HIMS) showcased strong performance, innovation, and resilience in Q3, driving revenue growth, subscriber base expansion, and improved profitability.
While challenges like achieving positive net income and balancing growth with new category launches exist, the company's strategic initiatives and focus on customer value creation position it for future success.
Opportunities in the weight management category, personalized products, and efficiency gains present avenues for HIMS to capitalize on market trends and enhance its competitive edge.
With a solid financial position, a clear marketing strategy, and a commitment to customer engagement, HIMS is poised for continued growth and value creation in the healthcare sector.

Hims & Hers Health reports stellar Q4 performance and growth outlook

Hims & Hers Health delivered a strong performance in Q4 2023, with robust revenue growth, positive net income, and expanded gross margins.
The company's focus on personalized solutions, subscriber growth, and financial strength positions it well for future growth and market expansion.
While facing challenges in managing costs and margin expansion, HIMS has opportunities to drive revenue growth, enhance user experience, and offer a diverse product range.
By balancing its strengths, addressing challenges, and seizing opportunities, Hims & Hers Health is poised for continued success in the healthcare market.

Hims & Hers Health reports stellar Q1 results and eyes expansion

Hims & Hers Health's Q1 2024 performance reflects strong financial growth, driven by record subscriber numbers and revenue increase, underpinned by a strategic focus on personalized care and enhancing customer experience.
The company's strengths lie in their ability to drive consumer adoption through user-friendly solutions, capitalize on the rapid growth of the Hers segment, and maintain consumer confidence through strategic pricing initiatives.
While facing challenges in scaling operations and managing increased capital expenditures, HIMS has ample opportunities to expand their offerings, invest in new product categories, and drive further revenue growth through strategic pricing adjustments.

Hims & Hers Health posts stellar Q2 results, eyes revenue diversification

Hims & Hers Health (HIMS) reported impressive Q2 performance, with strong revenue growth and subscriber additions.
The company's strategic initiatives in weight management and sterile compounded medications position it for future success.
While facing challenges in data availability and market dynamics, Hims & Hers has opportunities for revenue diversification and enhanced customer engagement.

Hims & Hers Health (HIMS) reports stellar Q3 results and eyes growth through personalized healthcare

Hims & Hers Health's Q3 performance reflects strong revenue growth, subscriber expansion, and improved profitability, positioning the company for continued success.
While facing challenges in retention and operational efficiency, the company's strategic initiatives and market positioning offer opportunities for sustained growth and innovation.
With a focus on personalized healthcare solutions and social responsibility, Hims & Hers Health is well-positioned to capitalize on market opportunities and drive long-term value for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hims was founded in November 2017 after Andrew Dudum was called out by his sister for having dry skin and breakouts. After she ordered him expensive products to address his issues, Dudum realized that men don't have the same options as women when it comes to purchasing wellness products. 

Now with radiant skin, Andrew Dudum and Jack Abraham co-found HIMS as an Atomic (VC fund) portfolio company. The company initially sells hair loss treatments, biotin vitamins, shampoo, and erectile dysfunction treatments. 

The company raises $7 million in Series A from M/C Partners, SV Angel and Thrive Captial, putting its pre-money valuation at $13 million.

Hims raises $40 million in Series B led by IVP and Redpoint Ventures, putting its pre-money valuation at $160 million. 

Hims launches a women's brand, Hers. 

Hers offers telemedicine services, birth control, and non-prescription hair and skin-care products. 

The company partners with A-list couple Jennifer Lopez and Alex Rodriguez, who work with the company on the launch of new products. 

Hims raises $297 million in Series C funding led by DCM Ventures, NewView Capital, McKesson Ventures, putting its valuation at $1 billion.

Hims and Hers expands into virtual mental health services led by licensed professionals, with support groups available free of charge during the COVID-19 pandemic. 

The company now provides access to medical care and treatment for more than a dozen conditions with more than 50 products, and has facilitated 1 million medical visits through its telehealth platforms in 2019. 

Hims goes public through a merger with a blank-check company Oaktree Acquisition Corp at $1.6 billion valuation.

forhims.com/aboutus
forhims.com/investors
SEC
CNBC
Business Insider
Bloomberg
Crunchbase
Axios

One of the most well-known NFL players is partnering with a health care company to bring awareness to men's health issues and treatment. What Happened: Tampa Bay Buccaneers tight end Rob Gronkowski has signed a partnership with Hims & Hers Health Inc (NYSE: HIMS).

Gronk Spike: Hims & Hers Signs Rob Gronkowski To Partnership

Hims & Hers Health Inc (NYSE: HIMS) has announced that Spencer Lee will step down as its Chief Financial Officer. Lee will lead a six-month transition plan and continue to support the company until a new CFO is appointed to ensure a smooth transition.

Hims & Hers Health CFO To Step Down; Reaffirms Outlook

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers partners with Rob Gronkowski to bring awareness to men's health issues and treatment.

Hims & Hers Partners With Rob Gronkowski to Bring Awareness to Men's Health Issues and Treatment

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the multi-specialty telehealth platform that provides modern personalized health and wellness experiences to consumers, today announced that Spencer Lee plans to step down from his role as the company's Chief Financial Officer. Lee, who joined the company in March 2019, will lead a six month transition plan and continue to support the company until a new CFO is appointed to ensure a smooth transition.

Spencer Lee to Step Down as Hims & Hers Health Chief Financial Officer

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers has appointed Mike Chi as the company's first-ever Chief Growth Officer.

Following Strong Growth, Hims & Hers Appoints Chief Growth Officer

Hims & Hers is a consumer healthcare brand targeting young digitally native consumers and stigmatized disorders. Hims & Hers management is building a track record of strong growth, scalability, and underpromising and overdelivering.

Time To Buy Hims & Hers

The stock now trades at an all-time low. Investors are too fearful to even consider this stock. Meanwhile, Hims & Hers continues to grow at a strong rate, with impressive guidance ahead.

Hims & Hers Stock: Trading At All-Time Lows, Worth Considering A Buy

This stock's share price is not matching up with the company's underlying performance. Let's investigate.

What the Market Is Missing About Hims & Hers Health

New week, new price target decrease from an analyst.

Why Hims & Hers Health Fell by Nearly 11% Today

Hims & Hers Health Inc (NYSE: HIMS) is trading higher Thursday after the company announced better-than-expected second-quarter financial results and issued guidance above estimates. Hims & Hers Health reported a quarterly earnings loss of 5 cents per share, which beat the estimate for a loss of 10 cents per share.

Why Hims & Hers Health Shares Are Trading Higher Today

Shares of the telehealth company rose on better-than-expected second-quarter results.

Why Hims & Hers Health Stock Popped Today

Investors need to pay close attention to Hims & Hers (HIMS) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Hims & Hers (HIMS) Stock?

A multi-specialty telehealth platform provider, Hims & Hers Health Inc (NYSE: HIMS), reported Q2 sales increased 69% Y/Y to $60.7 million, beating the consensus of $56.49 million.  "This was a quarter of very strong execution, as we continued to drive consistent organic revenue growth across our business, from our core categories to the newer mental health services," said Andrew Dudum, CEO and co-founder.

Hims & Hers Stock Shoot Up - What You Need To Know

Hims & Hers Health, Inc. (HIMS) CEO Andrew Dudum on Q2 2021 Results - Earnings Call Transcript

Hims & Hers Health Inc (NYSE: HIMS) shares are trading higher by 13.1% at $8.48 in Wednesday's after-hours session after the company reported better-than-expected second-quarter EPS and sales results and issued third-quarter 2021 revenue guidance above estimates. Hims & Hers Health reported quarterly losses of 5 cents per share which beat the analyst consensus estimate of a loss of 10 cents per share.

What's Going On With Hims & Hers Health's Stock After Hours?

Shares of Hims & Hers Health Inc. HIMS, -3.44% jumped 12% in extended trading Wednesday after the health-care company reported fiscal second-quarter results. Hims & Hers reported a net loss of $9.1 million, or 5 cents a share, compared with a net loss of $927,000, or 3 cents a share, in the year-ago quarter.

Hims & Hers stock jumps 12% on better-than-expected revenue, earnings

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, today reported financial results for the second quarter ending June 30, 2021. "This was a quarter of very strong execution, as we continued to drive consistent organic revenue growth across our business, from our core categories to the newer mental health services" said Andrew Dudum, CEO and co-founder o

Hims & Hers Health, Inc. Reports Second Quarter 2021 Financial Results

Hims & Hers common shares have fallen materially in recent months and its new price presents an opportunity to reevaluate the company. The company is on track to hit total revenue for fiscal 2021 of at least $221 million. It also sports a high gross profit margin.

Hims & Hers: Collapse Comes With Risks And Opportunities For Its Investors

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers, will release fiscal second quarter financial results on Wednesday, August 11, 2021 after market close, with a conference call to follow at 5:00 p.m. E.T. Conference Call Details The conference call can be accessed by dialing (833) 900-2256 for U.S. participants and (236) 714-27

Hims & Hers Health, Inc. to Announce Second Quarter 2021 Financial Results and Host Conference Call

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers releases survey findings on the pandemic's impact on Americans' mental health.

The Pandemic's Impact on Americans' Mental Health: New Hims & Hers Survey Shows 70% Remain Anxious Around Post-Pandemic ‘Normal', Half Have Considered Therapy for the First Time

The Pandemic's Impact on Americans' Mental Health: New Hims & Hers Survey Shows 70% Remain Anxious Around Post-andemic ‘Normal', Half Have Considered Therapy for the First Time

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company,” NYSE: HIMS), the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers, today announced that it will redeem all of its outstanding warrants (the “Warrants”) to purchase shares of the Company's Class A common stock, par value $0.0001 per share (the “Common Stock”), that were issued under the Warrant Agreement, dated July 22, 2019 (t

Hims & Hers Announces Redemption of All Outstanding Warrants

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers expands focus on sexual health with new product bundles.

Hims & Hers Expands Focus on Sexual Health With New Product Bundles

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers has finalized the acquisition of teledermatology specialist, Apostrophe.

Hims & Hers Completes Acquisition of Apostrophe

The potential for expansion coupled with a highly competitive pharmacy market has a BofA Securities analyst sidelined on shares of Hims & Hers Health, Inc. (NYSE:HIMS). The Hims Analyst: Michael Cherny initiated coverage on shares of Hims & Hers Health, Inc. with a Neutral rating and $12 price target.

News for Hims & Hers Health Stock (HIMS)